Sevoflurane preconditioning attenuates myocardial ischemia/reperfusion injury via caveolin-3-dependent cyclooxygenase-2 inhibition
about
Peri-operative anaesthetic myocardial preconditioning and protection - cellular mechanisms and clinical relevance in cardiac anaesthesiaModulation of caveolins, integrins and plasma membrane repair proteins in anthracycline-induced heart failure in rabbits.Metabolic and Functional Evaluation of the Heart and Lungs in Pulmonary Hypertension by Gated 2-[18F]-Fluoro-2-deoxy-D-glucose Positron Emission TomographyPulmonary hypertension: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases.A bioengineered hydrogel system enables targeted and sustained intramyocardial delivery of neuregulin, activating the cardiomyocyte cell cycle and enhancing ventricular function in a murine model of ischemic cardiomyopathy.Sevoflurane postconditioning protects rat hearts against ischemia-reperfusion injury via the activation of PI3K/AKT/mTOR signalingThe crossroads of iron with hypoxia and cellular metabolism. Implications in the pathobiology of pulmonary hypertension.Sevoflurane ameliorates intestinal ischemia-reperfusion-induced lung injury by inhibiting the synergistic action between mast cell activation and oxidative stress.Sevoflurane Preconditioning Reduces Intestinal Ischemia-Reperfusion Injury: Role of Protein Kinase C and Mitochondrial ATP-Sensitive Potassium Channel.Increased Mutagen Sensitivity and DNA Damage in Pulmonary Arterial Hypertension.Sevoflurane preconditioning in on-pump coronary artery bypass grafting: a meta-analysis of randomized controlled trials.Metabolic reprogramming and inflammation act in concert to control vascular remodeling in hypoxic pulmonary hypertension.TIR/BB-loop mimetic AS-1 attenuates cardiac ischemia/reperfusion injury via a caveolae and caveolin-3-dependent mechanism.Potential Roles of Serum Caveolin-3 Levels in Patients with Atrial Fibrillation.Canonical and new generation anticancer drugs also target energy metabolism.The role of nuclear imaging in pulmonary hypertension.Early detection of pulmonary arterial hypertension.Caveolae: molecular insights and therapeutic targets for stroke.Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report.One-year outcome of the sevoflurane in acute myocardial infarction randomized trial.Caveolin-3 plays a critical role in autophagy after ischemia-reperfusion.Caveolin-1/-3: therapeutic targets for myocardial ischemia/reperfusion injury.Inhibition of PKCβ2 overexpression ameliorates myocardial ischaemia/reperfusion injury in diabetic rats via restoring caveolin-3/Akt signaling.Epidemiology and treatment of pulmonary arterial hypertension.Circulating microRNAs indicate cardioprotection by sevoflurane inhalation in patients undergoing off-pump coronary artery bypass surgery.Molecular imaging of the pulmonary circulation in health and disease.Effects of Sevoflurane and Propofol on Organ Blood Flow in Left Ventricular Assist Devices in Pigs.Sevoflurane preconditioning ameliorates traumatic spinal cord injury through caveolin-3-dependent cyclooxygenase-2 inhibition.The allosteric glycogen synthase kinase-3 inhibitor NP12 limits myocardial remodeling and promotes angiogenesis in an acute myocardial infarction model.Translational Advances in the Field of Pulmonary Hypertension. From Cancer Biology to New Pulmonary Arterial Hypertension Therapeutics. Targeting Cell Growth and Proliferation Signaling Hubs.Upregulation of vascular endothelial growth factor receptor-1 contributes to sevoflurane preconditioning-mediated cardioprotection.
P2860
Q28085567-513CB947-E9E5-4DB1-B0B7-B60EB11E0D0BQ33675082-3452BA5B-1531-43EB-960E-280903D48E01Q33788499-88AFFCBF-636A-4D29-9368-7A5DFA83F01FQ33956819-E5652888-78C1-4DE5-81C5-478D379866D4Q34149206-1F94B426-909E-4202-A689-AC24E4B8C1C7Q34628699-4621822A-BBF8-4AB8-B7DF-D017DD09F417Q34924892-72137F26-47F7-43B4-AD48-C67D8DF89003Q35628595-13AC0E16-D976-43AC-82B5-51900726B289Q35822771-500AFDA3-1746-4B9A-8545-EEF0BFBD73C2Q35941642-06B7660D-A62E-4383-A609-A8778E5762D3Q36105332-39BB1B12-D73E-4CE8-8020-000A6E13D9FDQ36752368-685F5B71-918C-40F8-A45C-CE816B54EEC0Q37698757-AEAEC748-299F-45E5-9C0D-5C708EDF0250Q37735999-0806932B-B4F7-4C3B-B019-E0B11BBB52CFQ38208982-2617AB08-5550-4E52-91DF-C9688B66B711Q38243749-AD7A108F-8C91-4315-BEBC-7B98427ABD14Q38271027-BF798B60-80D9-469A-AE52-EA57B89FD691Q38339343-262D366C-06F0-48CC-A9A2-E06EA605C09AQ38403596-65C22DEC-2109-49E6-BCA8-A32920626B49Q38405526-B78E68DE-9065-41D2-9F01-0F0C1265303BQ38739373-322FA110-DD8E-4C9E-9E6E-3FFCF071AA5AQ38855645-127E6413-6EC5-4FB3-8CA3-BC12E9B9EB43Q38890008-2128517D-32D3-4149-985A-F458FBC0FC45Q39359218-59030886-F4D3-46FC-AA4B-D68ADFE8CD55Q41967015-108F705E-50EF-41B7-BD13-BA66ED5C649EQ42961033-BC44ED3E-E7F5-4B83-875F-7A02AF5490B8Q43184356-85CDA56F-1A10-4FA3-B39A-3803DF011C34Q47138142-AF401E85-1784-4EB6-88BC-E3961F041DF9Q47598692-9F98ECC2-BC7D-47E3-9EB4-BB7E49EC0D41Q49471057-F328D69A-9321-456C-B619-E6BF8348EF8DQ54968948-31F68CB9-1218-430C-91BF-C1869BEC59F0
P2860
Sevoflurane preconditioning attenuates myocardial ischemia/reperfusion injury via caveolin-3-dependent cyclooxygenase-2 inhibition
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Sevoflurane preconditioning at ...... nt cyclooxygenase-2 inhibition
@en
type
label
Sevoflurane preconditioning at ...... nt cyclooxygenase-2 inhibition
@en
prefLabel
Sevoflurane preconditioning at ...... nt cyclooxygenase-2 inhibition
@en
P2093
P2860
P1433
P1476
Sevoflurane preconditioning at ...... nt cyclooxygenase-2 inhibition
@en
P2093
Baojiang Liu
Jianli Zhao
Liyuan Jiao
Walter J Koch
Wayne Bond Lau
Xin-Liang Ma
Yajing Wang
P2860
P304
P356
10.1161/CIRCULATIONAHA.112.000045
P407
P433
11 Suppl 1
P577
2013-09-01T00:00:00Z